Edition:
United Kingdom

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

1,982.00INR
18 May 2018
Change (% chg)

Rs4.85 (+0.25%)
Prev Close
Rs1,977.15
Open
Rs1,982.80
Day's High
Rs1,992.00
Day's Low
Rs1,967.35
Volume
507,296
Avg. Vol
536,604
52-wk High
Rs2,787.00
52-wk Low
Rs1,901.15

Select another date:

Tue, Apr 24 2018

BRIEF-Dr.Reddy's Labs Gets EIR From USFDA For API Mirfield Plant, UK

* GETS ESTABLISHMENT INSPECTION REPORT FROM US FDA FOR API MIRFIELD PLANT, UK Source text for Eikon: Further company coverage:

BRIEF-Dr.Reddy's Laboratories Gets EIR From US FDA For API Cuernavaca Plant In Mexico

* SAYS GETS EIR FROM US FDA FOR API CUERNAVACA PLANT IN MEXICO Source text: https://bit.ly/2H9URmM Further company coverage:

BRIEF-Dr.Reddy's Labs' U.S. Unit Announces ANDA Filing For Migraine Candidate

* CO, U.S. UNIT PROMIUS PHARMA ANNOUNCE FILING OF AN NDA FOR MIGRAINE CANDIDATE

BRIEF-Dr.Reddy's Laboratories Appoints Erez Israeli As Chief Operating Officer

* CHIEF OPERATING OFFICER ABHIJIT MUKHERJEE TO RETIRE ON MARCH 31

BRIEF-Dr.Reddy's Labs Gets Form 483 With 4 Observations For API Hyderabad Plant Audit

* SAYS AUDIT OF API HYDERABAD PLANT IN TELENGANA BY U.S. FDA COMPLETED ON MARCH 16

BRIEF-Dr.Reddy's Laboratories Launches Levocetirizine Dihydrochloride Tablets USP, 5 Mg In U.S.

* ANNOUNCES LAUNCH OF LEVOCETIRIZINE DIHYDROCHLORIDE TABLETS USP, 5 MG IN U.S. MARKET Source text - http://bit.ly/2FUOwea Further company coverage:

BRIEF-India's Dr.Reddy's Laboratories Gets 5 Observations From U.S FDA For API Unit At Hyderabad ‍​

* U.S FDA ISSUES FORM 483 WITH 5 OBSERVATIONS FOR API UNIT AT HYDERABAD ‍​ Source text - http://bit.ly/2IehGDn Further company coverage:

BRIEF-Dr.Reddy's Laboratories Says Amended Complaint w.r.t U.S. Class Action Lawsuit Filed

* W.R.T U.S. CLASS ACTION LAWSUIT, AMENDED COMPLAINT FILED BY PLAINTIFF WHERE CHAIRMAN, COO AND U.S. UNIT ADDED AS DEFENDANTS Source text - http://bit.ly/2CvdcnN Further company coverage:

BRIEF-Dr.Reddy's Lab Announces Launch Of Tetrabenazine Tablets In U.S. Market

* SAYS ANNOUNCEMENT OF LAUNCH OF TETRABENAZINE TABLETS IN U.S. MARKET Source text - http://bit.ly/2GH4t5d Further company coverage:

India's Dr. Reddy's third-quarter profit tumbles, hit by U.S. pricing pressure

Indian generic drugmaker Dr. Reddy's Laboratories Ltd said quarterly net profit slumped nearly 40 percent, its third consecutive quarter of declines as pricing pressures in the United States hit sales.

Select another date: